Literature DB >> 32172994

Transient MOG antibody seroconversion associated with immunomodulating therapy.

Marc Pawlitzki1, Christin Campe2, Leoni Rolfes3, Hans-Jochen Heinze4, Frank Leypoldt5, Klaus-Peter Wandinger6, Markus Reindl7, Brigitte Wildemann8, Sven Jarius8, Peter Körtvelyessy9.   

Abstract

Immunoglobulin G (IgG) autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG) have recently been associated with autoimmune CNS demyelination. We present the case of a 35-year-old patient who was seronegative for MOG-IgG (as confirmed by means of three independent immunoassays) during two corticosteroid-responsive attacks of brainstem encephalitis and optic neuritis, respectively, but turned positive for MOG-IgG under treatment with interferon-beta (IFN-beta), which was commenced 6 months after onset of the first attack. MOG-IgG serum levels declined after therapy was switched to glatiramer acetate. The fact that seroconversion was first observed under treatment with IFN-beta is in accordance with previous evidence suggesting a role of IFN-beta in disease exacerbation in antibody-mediated disorders.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Year:  2019        PMID: 32172994     DOI: 10.1016/j.msard.2019.101420

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  1 in total

1.  Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment.

Authors:  Keita Takahashi; Hideyuki Takeuchi; Ryoko Fukai; Haruko Nakamura; Keisuke Morihara; Yuichi Higashiyama; Toshiyuki Takahashi; Hiroshi Doi; Fumiaki Tanaka
Journal:  Front Immunol       Date:  2021-02-15       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.